Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more
Market Cap & Net Worth: Iteos Therapeutics Inc (ITOS)
Iteos Therapeutics Inc (NASDAQ:ITOS) has a market capitalization of $448.68 Million ($448.68 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12216 globally and #5306 in its home market, demonstrating a -0.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Iteos Therapeutics Inc's stock price $10.15 by its total outstanding shares 44205400 (44.21 Million).
Iteos Therapeutics Inc Market Cap History: 2020 to 2025
Iteos Therapeutics Inc's market capitalization history from 2020 to 2025. Data shows change from $1.50 Billion to $448.68 Million (-11.61% CAGR).
Index Memberships
Iteos Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.02% | #334 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1214 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #189 of 263 |
Weight: Iteos Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Iteos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Iteos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.70x
Iteos Therapeutics Inc's market cap is 9.70 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.06 Billion | $344.77 Million | $214.52 Million | 5.97x | 9.59x |
| 2022 | $863.33 Million | $267.63 Million | $96.65 Million | 3.23x | 8.93x |
| 2023 | $484.05 Million | $12.60 Million | -$112.64 Million | 38.43x | N/A |
| 2024 | $339.50 Million | $35.00 Million | -$134.41 Million | 9.70x | N/A |
Competitor Companies of ITOS by Market Capitalization
Companies near Iteos Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Iteos Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Iteos Therapeutics Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Iteos Therapeutics Inc's market cap moved from $1.50 Billion to $ 448.68 Million, with a yearly change of -11.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $448.68 Million | +32.16% |
| 2024 | $339.50 Million | -29.86% |
| 2023 | $484.05 Million | -43.93% |
| 2022 | $863.33 Million | -58.05% |
| 2021 | $2.06 Billion | +37.67% |
| 2020 | $1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Iteos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $448.68 Million USD |
| MoneyControl | $448.68 Million USD |
| MarketWatch | $448.68 Million USD |
| marketcap.company | $448.68 Million USD |
| Reuters | $448.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.